For J&J, $30B Actelion deal is less about synergies, more about future promise
Biotech dealmaking such as the one by J&J underscore big pharma's hunt for new markets as opposed to making synergies the primary purpose to drive growth.
Johnson & Johnson’s device subsidiary gets into value-based analytics
Johnson & Johnson Medical Device Companies' new CareAdvantage offering program analyzes data from a health system’s operations to build an action plan that includes developing clinical pathways, workflow efficiency improvement, patient engagement and metrics linked to the care provider's goals.
Reducing Clinical and Staff Burnout with AI Automation
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Should J&J buy Edwards Lifesciences?
Johnson & Johnson's chief executive is on the hunt for a structural heart company to add to its medical devices business. Does it make sense to buy a company that is the big name in the market?
Security flaws leave J&J insulin pumps vulnerable to hacking
J&J, based in New Brunswick, New Jersey, sent a letter to patients last week from its Animas subsidiary acknowledging three security vulnerabilities first brought to the company's attention six months ago.
J&J’s $4.32B Abbott Medical Optics deal bolsters eye surgery business
The deal is a win-win for both companies.
J&J believes heft will protect Remicade against biosimilar competition
Johnson & Johnson is hoping that its blockbuster drug will be protected through its network with large healthcare systems when biosimilar competition arrives to U.S. shores.
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
What were the 5 most interesting things about J&J’s Q3 earnings?
Johnson & Johnson (NYSE: JNJ) had some good news for analysts in its third quarter earnings report. Profits rose to $2.98 billion on revenues of Things are going well for new drugs but its medical device division is suffering under the weight of the Affordable Care Act and fewer surgical procedures. Here’s a highlight of […]
Organ-on-a-chip producer collaborates with Sanofi in medtech-pharma mashup
Pharmaceutical companies’ search for ways to trim costs on research and development is leading them to try out some alternative technologies to achieve that. Organ-on-a-chip, aka human-on-a-chip, fits that description. Sanofi US is collaborating with Hurel, a biotechnology startup with a platform that replicates the human liver using living cells. It will fund studies to […]
Biotech startup sees microchips as a human’s best friend in drug development, raises $9.2M
There’s a saying that people who see animals as ineffective and misleading subjects for drug testing like to use: Cancer has been cured many times already. In mice. A biotechnology startup has developed a technology platform it claims does a better job of indicating the effect drugs would have on humans in the preclinical phase […]